spec sheet8 rows
Gepirone spent more than two decades in regulatory purgatory before it ever reached a pharmacy shelf, and its story is really about how brutal the FDA approval bar can be even for a drug that eventually worked. Fabre-Kramer Pharmaceuticals (with Organon as an early partner) submitted gepirone for depression in the late 1990s and got rejected in 1999, then again after resubmission in 2001, again in 2003 to 2004, and a fourth time in 2007, each rejection hinging on inconsistent trial results even as some studies showed real separation from placebo. The company kept the compound alive through a formal dispute appeal granted in 2016, and the FDA finally approved gepirone extended-release as Exxua for major depressive disorder in September 2023, an almost 25-year odyssey from first submission to market. It is less a lost drug than a drug that got found again, after nearly disappearing for good.
- significantly reduced HAM-D-17 scores versus placebo in multiple controlled trials
- lower relapse rate (23% vs 35%) when continued versus discontinued after response
- comparatively low rates of sexual dysfunction and weight gain versus SSRIs
- nausea and dizziness reported in trials
- Gepirone's FDA journey involved 11 negative or failed trials against only 2 convincing positive ones, yet it was approved anyway in 2023 as Exxua, one of the most litigated approval records in recent FDA history.
Mechanism
Full at the receptor, an azapirone chemically related to buspirone; unlike SSRIs, it does not block serotonin reuptake, which is thought to explain its comparatively low rate of sexual dysfunction and weight gain.
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
Gepirone (approved in 2023 as Exxua) carries a boxed-style cardiac caution: it can prolong the QTc interval and is contraindicated in patients with a baseline QTc over 450 msec or congenital long QT syndrome, so its label requires an ECG and electrolyte check before starting, during titration, and periodically thereafter. Like other antidepressants it carries the class warning for increased suicidal ideation in patients under 25, and it should not be combined with MAOIs or used within 14 days of one because of serotonin-syndrome risk. The most common tolerability complaints in trials were dizziness, nausea, insomnia, abdominal pain, and dyspepsia. As a serotonergic agent it raises serotonin-syndrome risk when stacked with other serotonergic drugs, and dose should not be escalated while QTc remains prolonged.
Interactionsdocumented pairs only, not exhaustive
Gepirone carries two hard limits.
The first is metabolic. Gepirone is cleared by CYP3A4, so strong inhibitors such as ketoconazole, itraconazole, clarithromycin and ritonavir push its concentration high enough that the pairing is contraindicated. Moderate inhibitors raise exposure enough that the prescribing information calls for a reduced amount. Strong inducers such as rifampin, carbamazepine, phenytoin and St John's wort do the reverse and can strip the antidepressant effect away.
The second is cardiac. Gepirone prolongs QTc in a concentration dependent way, which is why the CYP3A4 problem is a safety problem and not just a potency one. Added to other QT prolonging agents, including class IA and class III antiarrhythmics, several antipsychotics, methadone and certain macrolides, it raises the risk of torsade de pointes; hypokalemia from diuretics makes that worse, and congenital long QT syndrome is itself a contraindication.
As a 5-HT1A agonist, gepirone also carries serotonergic risk. Monoamine oxidase inhibitors are contraindicated with a two week separation in either direction, and combining it with SSRIs or tricyclics can precipitate serotonin syndrome.
Checking a whole stack? Run it through interactions + stacks.
History
First submitted to the FDA by Fabre-Kramer/Organon in the late 1990s; rejected in 1999, 2001, 2003-2004, and 2007 despite multiple positive placebo-controlled trials. A formal dispute appeal was granted in 2016, and the FDA finally approved extended-release gepirone (Exxua) for major depressive disorder on September 29, 2023.
Resources
This entry is here for reference.
Research
- 1.Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder
- 2.Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study
2 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
Why did the FDA reject gepirone so many times?
The trial data was mixed; only 2 of roughly 13 submitted studies were unambiguously positive by FDA standards, even though the drug reliably beat placebo in several of them.
Is gepirone the same as buspirone?
They are chemical relatives, both azapirones acting on the 5-HT1A receptor, but gepirone was developed and studied specifically as an antidepressant rather than an anxiolytic.
Limitations of the evidence
- an FDA advisory committee voted 9-4 that the sponsor had not sufficiently demonstrated efficacy despite an 11-2 vote favoring its safety profile
- eleven of thirteen submitted trials were considered failed or negative by the FDA's own count
Adverse effects
- nausea and dizziness reported in trials